HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors.

ABSTRACT:

Purpose

Cancers overexpressing the HER2/neu gene are usually more aggressive and are associated with poor prognosis. Although trastuzumab has significantly improved the outcome, many tumors do not respond or acquire resistance to current therapies. To provide an alternative HER2-targeted therapy, we have developed and characterized a novel recombinant protein combining an HER2-specific Affibody and modified Pseudomonas aeruginosa exotoxin A (PE 38), which, after binding to HER2, is internalized and delivered to the cytosol of the tumor cell, where it blocks protein synthesis by ADP ribosylation of eEF-2.

Experimental design

The effect of the Affitoxin on cell viability was assessed using CellTiter-Glo (Promega). To assess HER2-specific efficacy, athymic nude mice bearing BT-

SUBMITTER: Zielinski R 

PROVIDER: S-EPMC3149757 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature